Intracranial pressure (ICP) is a measure of the pressure within the skull. Monitoring these levels is important for monitoring the state of a patient's brain. It is used to detect and treat increased pressure in the cranial cavity. This obstruction can present a significant risk to the patient's health and can be life threatening. ICP monitors measure the pressure inside the brain using a thin intraventricular catheter which is inserted through the patient’s skull or sometimes through the nose or ear. By using this information, medical professionals can monitor the patient’s ICP closely and detect any changes in the pressure level which could indicate a potential problem. The main purpose of ICP monitoring is to identify the symptoms of raised intracranial pressure before they become more serious, thus optimizing treatment and reducing the chances of further complications. Early detection of pressure changes can help medical professionals to implement the appropriate therapy to reduce the ICP. This can prevent permanent brain damage and even death in some cases. ICP monitoring also allows neurologists to assess the impact of medical treatments on the intracranial pressure. By using the data from ICP movements, medical professionals can assess how certain therapies are impacting the pressure and make more informed decisions on how to better manage a patient’s condition. Overall, ICP monitoring is an important tool used by medical professionals to both monitor and treat changes in intracranial pressure. It allows medical teams to act swiftly and prevent further damage to the brain, thus improving the prognosis of the patient.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom